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of therapeutic options for CHC patients. Some of them
have shown promising results in clinical trials. A number
of HCV polymerase inhibitors are in phase I or II trials
and entry inhibitors are under development. Two HCV
NS3 4A protease inhibitors (PIs) have completed phase
III studies. Data from phase 2 studies have shown that
a substantial number of HCV-1 patients could achieve an
SVR with DAA plus Peg-IFN/RBV for even 12 or 24 weeks.
Phase III studies of Boceprevir or Telaprevir demonstrated
PI/Peg-IFN/RBV (with or without “lead in” pretreatment)
based on strategy of week 4 response-guided therapy
could dramatically improve the SVR rates to 63 75% in
HCV-1 treatment-naive patients. In addition, the boceprevir
regimens consistently achieved SVR rates of approximately
40% to 50% among the more difﬁcult-to-treat patients, such
as blacks and previous nonresponders. However, subgroup
analysis demonstrated that the beneﬁts of adding boceprevir
was only observed among patients carrying unfavorable IL28
genotype. Therefore, excitement over these impressive
results needs to be tempered by the complexity of the
regimens, the high rates of anemia, and the development of
boceprevir resistance-associated variants, especially among
treatment-experienced patients.
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Antimicrobial resistance is getting a challenge and threat to
public healthcare, which was announced as one of the most
severe public healthcare crisis by WHO. Strategies for the
containment of AMR include resistant surveillance, resistant
mechanism study, prudent application of antimicrobial
agents and new antibiotic development, etc. It is very
important to clinicians to prescribe antibiotics referring
to the bacterial resistant monitoring results, and resistant
mechanism researches would elucidate the biological basis
of antibiotic resistance and provide basic information for
overcoming AMR and ﬁnding new antibiotic target. The
national and local bacterial resistant surveillance networks
have been set up and the researches on the resistant
mechanisms have achieved much valuable results.
1. Antibiotic resistant surveillance networks in China:
Companying with the social-economic development, health-
care improvement, lifespan elongation and communicable
disease decrement, infections, especially nosocomial
infections and infections with resistant germs are emerging
as one of the major morbidity and mortality in
China. Bacterial resistance has got also an unavoidable
public health problem. It is becoming a consensus of
clinician, microbiologist, pharmacist, healthcare ofﬁcials
and pharmaceutical companies to investigate bacterial
resistance, study resistant mechanisms and ﬁnd out
effective handling measures. Ofﬁcial facilities, medical
institutions and pharmaceutical companies conducted most
of the bacterial resistant surveillance.
Ofﬁcial bacterial resistance surveillance: The national and
provincial antimicrobial resistant surveillance networks
were established after 2005, the national network is named
Mohnarin (MOH national antibacterial resistant investigation
net ) because of the initiation of MOH in 2005, the
major mission of Mohnarin is to get national bacterial
resistant information and assist the antimicrobial agent
administration in China. This network was composed of some
150 tertiary hospitals across the country. All the hospitals
conduct surveillance by a common protocol, but each
hospital do not need to modify its own routine daily clinical
microbiological schedule, such as bacterial identiﬁcation,
antibiotic sensitive panel. The investigational results are
submitted to Mohnarin Center for data analysis. WHONET
software is employed for data processing. For promotion
the surveillance quality, there are some training course
and workshop focusing on the QC/QA and Whonet software
use. Mohnarin should generate yearly report to MOH. By
the regulation of MOH, some provinces have their own
AMR surveillance network, which consist of both tertiary
hospitals and primary hospitals. Mohnarin is not only the
largest network and but also the high quality one.
Medical institution bacterial resistance surveillance: Most
of tertiary hospitals in China have their regular or irregular
bacterial resistant surveillance carried out by their clinical
microbiology units or nosocomial monitoring facilities.
Pharmaceutical company bacterial resistant surveillance:
For the purpose of getting bacterial resistance to some
special antibacterial agent, some pharmaceutical company
occasionally organized bacterial resistant surveillance.
Although with participation of scientiﬁc members, the
business aim makes the clinical value of the results is
limited.
2. Prevalence of bacterial resistance: By the results
of Mohnarin 2008, 160513 bacterial isolates and their
antibacterial susceptibility data were collected during the
survey period in 89 tertiary hospitals, which included
50856 (31.68%) Gram-positive and 106957(68.32%) Gram-
negative bacterial strains. Staphylococcus (32378 strains),
enterococcus (12127 strains) and streptococcus (5138
strains) were the top three gram-positive isolates, while
Escherichia coli (26957 strains), Pseudomonas aeruginosa
(18347 strains) and Klebsiella pneumoniae (16396 strains)
were the most common Gram-negative isolates. Methicillin-
resistant Staphylococcus aureus (MRSA) and Staphylococcus
epidermidis were 67.6% and 83.2%, respectively; 3.8%
of Streptococcus pneumoniae was penicillin resistant.
Glycopeptides resistant enterococcus was rare. More than
40% of E. coli and other enterobacteria were resistant to
